SEARCH

SEARCH BY CITATION

References

  • 1
    Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis 2008; 5: A74. Available at: http://www.cdc.gov/pcd/issues/2008/jul/07_0155.htm. Accessed on May 17, 2011.
  • 2
    Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
  • 3
    El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763.
  • 4
    Massarweh NN, Park JO, Farjah F, Yeung RS, Symons RG, Vaughan TL, et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2010; 210: 441-448.
  • 5
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
  • 6
    Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., eds. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. 2011. Available at: http://seer.cancer.gov/csr/1975_2008/. Accessed November 2, 2011.
  • 7
    Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004; 27( Suppl 1): S126-S132.
  • 8
    Abrams P, Marsh JW. Current approach to hepatocellular carcinoma. Surg Clin North Am 2010; 90: 803-816.
  • 9
    Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453-469.
  • 10
    World Health Organization. International Classification of Diseases for Oncology. Geneva: World Health Organization; 1976.
  • 11
    Percy C, Van Holten V, Muir C, eds. International Classification of Diseases for Oncology, 2nd ed. Geneva: World Health Organization; 1990.
  • 12
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al., eds. International Classification of Diseases for Oncology, 3rd ed. Geneva: World Health Organization; 2000.
  • 13
    Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-351.
  • 14
    Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010; 102: 1584-1598.
  • 15
    Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010; 30: 3-16.
  • 16
    Lencioni R. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 2010; 78( Suppl 1): 107-112.
  • 17
    U.S. Department of Health and Human Services. Healthy People 2020. Washington, DC: U.S. Department of Health and Human Services. 2011. Available at: http://www.healthypeople.gov. Accessed November 2, 2011.
  • 18
    AC McClune, MJ Tong. Chronic Hepatitis B and hepatocellular carcinoma. Clin Liver Dis 2010; 14: 461-476.
  • 19
    Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010; 116: 1367-1377.
  • 20
    Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci 2009; 54: 2031-2039.
  • 21
    Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early stage hepatocellular carcinoma. Arch Surg 2010; 145: 1158-1163.
  • 22
    Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 2011; 35: 858-867.
  • 23
    Yang JD, Harmsen WS, Slettedahl SW, Chaiteerakij R, Enders FT, Therneau TM, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011 Apr 1. doi: 10.1016/j.cgh.2011.03.027.
  • 24
    London WT, McGlynn KA. Liver cancer. In: Schottenfeld D, Fraumeni JF, Jr., eds. Cancer Epidemiology and Prevention (3rd ed.). New York: Oxford University Press; 2006: 763-786.
  • 25
    El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. HEPATOLOGY 2001; 33: 62-65.
  • 26
    Organ Procurement and Transplantation Network. 2011. Available at: http://optn.transplant.hrsa.gov. Accessed November 2, 2011.